These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 7932054)
1. Prolonged anti-emetic activity and 5-HT3-receptor antagonism by BRL 46470 in conscious ferrets. Bermudez J; Sanger GJ J Pharm Pharmacol; 1994 Jun; 46(6):520-1. PubMed ID: 7932054 [TBL] [Abstract][Full Text] [Related]
2. BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties. Blackburn TP; Baxter GS; Kennett GA; King FD; Piper DC; Sanger GJ; Thomas DR; Upton N; Wood MD Psychopharmacology (Berl); 1993; 110(3):257-64. PubMed ID: 7831418 [TBL] [Abstract][Full Text] [Related]
3. Emetic activity of zacopride in ferrets and its antagonism by pharmacological agents. Sancilio LF; Pinkus LM; Jackson CB; Munson HR Eur J Pharmacol; 1990 Jun; 181(3):303-6. PubMed ID: 2384137 [TBL] [Abstract][Full Text] [Related]
4. The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Fukuda T; Setoguchi M; Inaba K; Shoji H; Tahara T Eur J Pharmacol; 1991 Apr; 196(3):299-305. PubMed ID: 1654255 [TBL] [Abstract][Full Text] [Related]
5. Relationship of serotonin-3 receptor antagonist activity to gastric emptying and motor-stimulating actions of prokinetic drugs in dogs. Gullikson GW; Loeffler RF; Viriña MA J Pharmacol Exp Ther; 1991 Jul; 258(1):103-10. PubMed ID: 2072288 [TBL] [Abstract][Full Text] [Related]
6. Emesis and defecations induced by the 5-hydroxytryptamine (5-HT3) receptor antagonist zacopride in the ferret. King GL J Pharmacol Exp Ther; 1990 Jun; 253(3):1034-41. PubMed ID: 2162943 [TBL] [Abstract][Full Text] [Related]
7. RS 42358-197, a novel and potent 5-HT3 receptor antagonist, in vitro and in vivo. Eglen RM; Lee CH; Smith WL; Johnson LG; Whiting RL; Hegde SS J Pharmacol Exp Ther; 1993 Aug; 266(2):535-43. PubMed ID: 8355189 [TBL] [Abstract][Full Text] [Related]
8. Studies on the emetic and antiemetic properties of zacopride and its enantiomers. Sancilio LF; Pinkus LM; Jackson CB; Munson HR Eur J Pharmacol; 1991 Jan; 192(3):365-9. PubMed ID: 2055236 [TBL] [Abstract][Full Text] [Related]
9. Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides. Youssefyeh RD; Campbell HF; Airey JE; Klein S; Schnapper M; Powers M; Woodward R; Rodriguez W; Golec S; Studt W J Med Chem; 1992 Mar; 35(5):903-11. PubMed ID: 1548679 [TBL] [Abstract][Full Text] [Related]
10. 5-HT3 receptor agonism may be responsible for the emetic effects of zacopride in the ferret. Middlefell VC; Price TL Br J Pharmacol; 1991 May; 103(1):1011-2. PubMed ID: 1831684 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and pharmacology of 3,4-dihydro-3-oxo-1,4-benzoxazine-8-carboxamide derivatives, a new class of potent serotonin-3 (5-HT3) receptor antagonists. Kawakita T; Kuroita T; Yasumoto M; Sano M; Inaba K; Fukuda T; Tahara T Chem Pharm Bull (Tokyo); 1992 Mar; 40(3):624-30. PubMed ID: 1611677 [TBL] [Abstract][Full Text] [Related]
12. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog. Fitzpatrick LR; Lambert RM; Pendley CE; Martin GE; Bostwick JS; Gessner GW; Airey JE; Youssefyeh RD; Pendleton RG; Decktor DL J Pharmacol Exp Ther; 1990 Aug; 254(2):450-5. PubMed ID: 2166791 [TBL] [Abstract][Full Text] [Related]
13. Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Fernández AG; Puig J; Beleta J; Doménech T; Bou J; Berga P; Gristwood RW; Roberts DJ Eur J Pharmacol; 1992 Nov; 222(2-3):257-64. PubMed ID: 1451737 [TBL] [Abstract][Full Text] [Related]
14. Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret. Bhandari P; Andrews PL Eur J Pharmacol; 1991 Nov; 204(3):273-80. PubMed ID: 1663456 [TBL] [Abstract][Full Text] [Related]
15. Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides. Youssefyeh RD; Campbell HF; Klein S; Airey JE; Darkes P; Powers M; Schnapper M; Neuenschwander K; Fitzpatrick LR; Pendley CE J Med Chem; 1992 Mar; 35(5):895-903. PubMed ID: 1312602 [TBL] [Abstract][Full Text] [Related]
16. Antiemetic activity of FK1052, a 5-HT3- and 5-HT4-receptor antagonist, in Suncus murinus and ferrets. Nakayama H; Yamakuni H; Higaki M; Ishikawa H; Imazumi K; Matsuo M; Mutoh S J Pharmacol Sci; 2005 Aug; 98(4):396-403. PubMed ID: 16079468 [TBL] [Abstract][Full Text] [Related]
17. Effects of 5-hydroxytryptamine 3 receptor antagonists on gastrointestinal motor activity in conscious dogs. Yoshida N; Mizumoto A; Iwanaga Y; Itoh Z J Pharmacol Exp Ther; 1991 Jan; 256(1):272-8. PubMed ID: 1846418 [TBL] [Abstract][Full Text] [Related]
18. Antiemetic effects of N-3389, a newly synthesized 5-HT3 and 5-HT4 receptor antagonist, in ferrets. Minami M; Endo T; Tamakai H; Ogawa T; Hamaue N; Hirafuji M; Monma Y; Yoshioka M; Hagihara K Eur J Pharmacol; 1997 Mar; 321(3):333-42. PubMed ID: 9085045 [TBL] [Abstract][Full Text] [Related]
19. Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis. Miner WD; Sanger GJ; Turner DH Br J Cancer; 1987 Aug; 56(2):159-62. PubMed ID: 3311109 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. Eglen RM; Lee CH; Smith WL; Johnson LG; Clark R; Whiting RL; Hegde SS Br J Pharmacol; 1995 Feb; 114(4):860-6. PubMed ID: 7773547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]